The impact of the AB0 and the Rhesus blood group system on outcomes in bladder cancer patients treated with radical cystectomy
- 240 Downloads
To investigate the impact of the AB0 and the Rhesus blood group system on outcomes of urothelial carcinoma of the bladder (UCB) patients treated with radical cystectomy (RC).
We included 511 UCB patients treated with RC without neoadjuvant chemotherapy from 1996 to 2011 at our institution. Cox and logistic regression models assessed the association of the AB0 blood group antigen and Rhesus factor expression with tumor biologic features and outcomes, respectively.
In total, 216 patients (42.3 %) had the blood group antigen A0, 73 patients (14.3 %) the antigen B0, 33 patients (6.4 %) the antigen AB and 189 patients (37.0 %) the antigen 00. In addition, 414 patients (81.0 %) were Rhesus factor positive. The AB0 blood group antigen expression was associated with a higher tumor grade (p = 0.003). In contrast, the Rhesus factor was not associated with any clinicopathologic characteristics. Neither the AB0 blood group antigens nor the Rhesus factor was associated with survival. In a sensitivity analysis of patients receiving adjuvant chemotherapy, however, the blood group antigen AB expression was associated with reduced cancer-specific and overall survival.
The AB0 blood group antigens and the Rhesus factor are not associated with survival. Although the AB0 blood groups and the Rhesus factor are analyzed in every patient treated with RC, they do not represent appropriate biomarkers for UCB outcome prognostication. The association of the AB0 blood group antigens with response to adjuvant chemotherapy requires further validation.
KeywordsUrinary bladder cancer AB0 blood group system Rhesus blood group system Urothelial carcinoma Radical cystectomy Outcome
Dr. Michael Rink is supported by the GEROK research Grant of the University of Hamburg.
Conflict of interest
The authors declare that they have no conflict of interest.
The study was approved by the institutional review board and does not contain human studies.
- 8.Wolpin BM, Kraft P, Gross M, Helzlsouer K, Bueno-de-Mesquita HB, Steplowski E et al (2010) Pancreatic cancer risk and ABO blood group alleles: results from the pancreatic cancer cohort consortium. Cancer Res 70(3):1015–1023. doi: 10.1158/0008-5472.can-09-2993 PubMedCentralCrossRefPubMedGoogle Scholar
- 11.Klatte T, Xylinas E, Rieken M, Rouprêt M, Fajkovic H, Seitz C et al (2014) Effect of ABO blood type on mortality in patients with urothelial carcinoma of the bladder treated with radical cystectomy. Urol Oncol Semin Orig Investig 32(5):625–630. doi: 10.1016/j.urolonc.2013.11.010 CrossRefGoogle Scholar
- 15.Lotan Y, Gupta A, Shariat SF, Palapattu GS, Vazina A, Karakiewicz PI et al (2005) Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol 23(27):6533–6539. doi: 10.1200/jco.2005.05.516 CrossRefPubMedGoogle Scholar
- 16.Novara G, Svatek RS, Karakiewicz PI, Skinner E, Ficarra V, Fradet Y et al (2010) Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. J Urol 183(6):2165–2170. doi: 10.1016/j.juro.2010.02.021 CrossRefPubMedGoogle Scholar
- 17.Bethesda MD (2012) Standards for blood banks and transfusion services. American Association of Blood Banks 28th editionGoogle Scholar
- 29.Beckmann L (2008) Racial and ethnic distribution of ABO blood types. http://www.bloodbook.com/world-abo.html; Accessed 09/18/2014